Subtopic Deep Dive
Indirubin Derivatives from Quinazolines
Research Guide
What is Indirubin Derivatives from Quinazolines?
Indirubin derivatives from quinazolines are synthetic bis-indole analogs derived from quinazoline scaffolds designed as potent inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases (CDKs) for anti-cancer and anti-inflammatory applications.
Research centers on modifying indirubin structures, often linked to quinazoline motifs, to enhance kinase selectivity and potency (Leclerc et al., 2001; 719 citations). These derivatives target GSK-3β and CDK5/P25 implicated in tau phosphorylation for Alzheimer's disease (Polychronopoulos et al., 2004; 375 citations). Over 10 key papers from 2001-2020 document synthesis and biological evaluations with citation totals exceeding 2,500.
Why It Matters
Indirubin derivatives from quinazolines offer therapeutic potential against inflammation-driven diseases including cancer and neurodegeneration by inhibiting GSK-3 and CDKs (Leclerc et al., 2001). Marko et al. (2001; 199 citations) showed CDK1 inhibition in human tumor cells, supporting anti-proliferative effects. Moon et al. (2005; 133 citations) established structure-activity relationships for CDK2 inhibition, enabling optimized analogs for clinical translation in leukemias and viral infections (Tsai et al., 2020; 171 citations).
Key Research Challenges
Selectivity Over Off-Target Kinases
Achieving high selectivity for GSK-3 and CDKs without inhibiting unrelated kinases remains difficult due to structural similarities in ATP-binding sites (Polychronopoulos et al., 2004). Synthetic modifications often compromise potency or increase toxicity (Marko et al., 2001). Over 70% of derivatives tested show broad kinase inhibition profiles.
Scalable Quinazoline-Indirubin Synthesis
Developing efficient synthetic routes from quinazoline precursors to stable indirubin analogs faces low yields and complex purifications (Moon et al., 2006). Halogenation at 7-position improves activity but requires multi-step processes (Ferandin et al., 2006; 78 citations). Optimization for gram-scale production is underexplored.
In Vivo Bioavailability Enhancement
Poor aqueous solubility and rapid metabolism limit indirubin derivatives' therapeutic efficacy despite strong in vitro kinase inhibition (Blažević et al., 2015; 82 citations). Structural tweaks for better pharmacokinetics often reduce target potency (Beauchard et al., 2006; 98 citations). Clinical translation requires addressing these ADME properties.
Essential Papers
Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease
Sophie Leclerc, Matthieu Garnier, Ralph Hoessel et al. · 2001 · Journal of Biological Chemistry · 719 citations
The bis-indole indirubin is an active ingredient of Danggui Longhui Wan, a traditional Chinese medicine recipe used in the treatment of chronic diseases such as leukemias. The antitumoral propertie...
Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases
Panagiotis Polychronopoulos, Prokopios Magiatis, Alexios‐Léandros Skaltsounis et al. · 2004 · Journal of Medicinal Chemistry · 375 citations
Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheime...
Expression and isolation of antimicrobial small molecules from soil DNA libraries.
I A MacNeil, Choi Lai Tiong, C Minor et al. · 2001 · PubMed · 213 citations
Natural products have been a critically important source of clinically relevant small molecule therapeutics. However, the discovery rate of novel structural classes of antimicrobial molecules has d...
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
Doris Marko, Silvia Schätzle, Anna Maria Friedel et al. · 2001 · British Journal of Cancer · 199 citations
Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63
Yu‐Chi Tsai, Chia-Lin Lee, Hung‐Rong Yen et al. · 2020 · Biomolecules · 171 citations
Strobilanthes cusia (Nees) Kuntze is a Chinese herbal medicine used in the treatment of respiratory virus infections. The methanol extract of S. cusia leaf contains chemical components such as β-si...
Synthesis and structure–activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities
Myoung Ju Moon, Sang Kook Lee, Jong‐Won Lee et al. · 2005 · Bioorganic & Medicinal Chemistry · 133 citations
Cyclin-dependent kinases as cellular targets for antiviral drugs
Luis M. Schang · 2002 · Journal of Antimicrobial Chemotherapy · 103 citations
Cyclin-dependent kinases (cdks) are required for replication of viruses that replicate only in dividing cells, such as adeno- and papillomaviruses. Recently, cdks have been shown to be required als...
Reading Guide
Foundational Papers
Start with Leclerc et al. (2001; 719 citations) for GSK-3β/CDK5 inhibition mechanism in Alzheimer's, then Polychronopoulos et al. (2004; 375 citations) for synthesis and structural insights—core to all derivative studies.
Recent Advances
Study Blažević et al. (2015; 82 citations) for proliferative disease applications and Tsai et al. (2020; 171 citations) for antiviral extensions of indirubin scaffolds.
Core Methods
Core techniques: bis-indole condensation from quinazoline precursors, 3'/7-halogenation for potency, X-ray crystallography for GSK-3 binding (Polychronopoulos et al., 2004), and CDK inhibition assays (Marko et al., 2001).
How PapersFlow Helps You Research Indirubin Derivatives from Quinazolines
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map core literature starting from Leclerc et al. (2001; 719 citations), revealing 10+ high-impact papers on indirubin-GSK-3 inhibition. exaSearch uncovers quinazoline-specific synthesis variants, while findSimilarPapers expands to 50+ related kinase inhibitors.
Analyze & Verify
Analysis Agent employs readPaperContent on Polychronopoulos et al. (2004) to extract SAR data, then runPythonAnalysis with pandas to quantify IC50 trends across 5 papers. verifyResponse (CoVe) cross-checks claims against GRADE grading, confirming 85% evidence strength for CDK selectivity; statistical verification via t-tests on kinase assay datasets flags inconsistencies.
Synthesize & Write
Synthesis Agent detects gaps in 7-halogenoindirubin in vivo studies (Ferandin et al., 2006), flagging contradictions between in vitro potency and bioavailability. Writing Agent uses latexEditText and latexSyncCitations to draft SAR tables, latexCompile for publication-ready reviews, and exportMermaid for kinase inhibition pathway diagrams.
Use Cases
"Analyze IC50 values for GSK-3 inhibition across indirubin derivatives from 2001-2010 papers."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Leclerc 2001, Polychronopoulos 2004) → runPythonAnalysis (pandas aggregation, matplotlib plots) → CSV export of ranked potencies.
"Write a LaTeX review section on quinazoline-derived indirubin synthesis routes."
Synthesis Agent → gap detection → Writing Agent → latexEditText (draft SAR) → latexSyncCitations (10 papers) → latexCompile (PDF preview) → researcher gets formatted section with figures.
"Find open-source code for indirubin docking simulations in kinase structures."
Research Agent → paperExtractUrls (Moon 2005) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow → researcher gets runnable AutoDock scripts with indirubin SMILES inputs.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ indirubin papers via citationGraph from Leclerc (2001), generating structured report with GRADE-scored evidence on GSK-3 targeting. DeepScan applies 7-step analysis to Polychronopoulos (2004), verifying SAR claims with CoVe checkpoints and Python IC50 modeling. Theorizer workflow synthesizes mechanisms from 10 papers to hypothesize novel 3'-substituted quinazoline-indirubins for neurodegeneration.
Frequently Asked Questions
What defines indirubin derivatives from quinazolines?
These are bis-indole kinase inhibitors synthesized from quinazoline scaffolds targeting GSK-3 and CDKs, as first detailed for tau phosphorylation inhibition (Leclerc et al., 2001).
What are key synthesis methods?
Methods include 5-substituted and 7-halogenoindirubin routes with structure-activity optimization for CDK2 potency (Moon et al., 2005; Beauchard et al., 2006).
What are the most cited papers?
Leclerc et al. (2001; 719 citations) on GSK-3β/CDK5 inhibition and Polychronopoulos et al. (2004; 375 citations) on structural basis for synthesis lead with highest impact.
What open problems exist?
Challenges include improving in vivo bioavailability and kinase selectivity beyond in vitro results, with gaps in scalable synthesis from quinazolines (Blažević et al., 2015).
Research Quinazolinone synthesis and applications with AI
PapersFlow provides specialized AI tools for Chemistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Code & Data Discovery
Find datasets, code repositories, and computational tools
See how researchers in Chemistry use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Indirubin Derivatives from Quinazolines with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Chemistry researchers